The Anti di-Ubiquitin K6 and K33 Affimers from Avacta are a unique range of binders, with no antibody or aptamer equivalents. The Affimer technology offers a number of essential advantages over other affinity technologies. Affimer binders are produced entirely in vitro and are therefore not restricted by the host immune system. The technology is ideally suited when dealing with difficult targets such as K6 and K33, the exact function of which is largely unknown due to the limited tools available. The Anti di-Ubiquitin Affimer range is human-specific and includes a variety of tagged binders displaying high affinities for poly-ubiquitin chains formed by K6 or K33 linkages, in protein expression studies.
This year’s controversial news included unethical behavior among politicians, a murder, and multiple accusations of gender discrimination and sexual harassment, in addition to the usual spate of research misconduct.